论文部分内容阅读
作者采用Ida和Ara-C组成的强烈化疗方案治疗预后差的MDS和继发于MDS的AML,取得较以往好的疗效。预后差的MDS病人19例(标准为:骨髓原始粒细胞>20％,或骨髓原始粒细胞在10％～20％之间但同时合并中性粒细胞<0.5×10~9或血小板<20％×10~9),AML病人21例(发病前至少有可证实的MDS病
The authors used a strong chemotherapy regimen consisting of Ida and Ara-C to treat poorly-prone MDS and AML secondary to MDS, achieving better results than before. 19 patients with poor prognosis of MDS (standard: bone marrow blasts> 20%, or bone marrow blasts between 10% and 20% but with neutrophils <0.5 × 10-9 or platelets <20% ×10~9) 21 patients with AML (at least confirmed MDS before onset)